Pentagon contract could send this $2 AI stock soaring

Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...

Kinney Horn Biography and Net Worth

Insider of Olema Pharmaceuticals

Mr. Horn has served as Chief Business Officer of Olema Oncology since May 2020. He joined the company from EcoR1 Capital, where he was an Entrepreneur in Residence. Before that, he was Director of Business Development at Genentech, Inc., where over 16 years he led oncology sourcing, evaluation and partnering efforts completing more than $30 billion in transactions. Earlier in his career, he held various investment banking and venture capital roles. He earned a B.A. in economics and international affairs from University of Mary Washington and an M.S. in biochemistry from Georgetown University.

What is Kinney Horn's net worth?: The estimated net worth of Kinney Horn is at least $70,410.00 as of August 10th, 2021. Mr. Horn owns 7,041 shares of Olema Pharmaceuticals stock worth more than $70,410 as of April 24th. This net worth evaluation does not reflect any other investments that Mr. Horn may own. Learn More about Kinney Horn's net worth.
How do I contact Kinney Horn?: The corporate mailing address for Mr. Horn and other Olema Pharmaceuticals executives is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. Olema Pharmaceuticals can also be reached via phone at 650-243-5555 and via email at [email protected]. Learn More on Kinney Horn's contact information.
Has Kinney Horn been buying or selling shares of Olema Pharmaceuticals?: Kinney Horn has not been actively trading shares of Olema Pharmaceuticals within the last three months. Most recently, Kinney Horn sold 5,253 shares of the business's stock in a transaction on Thursday, March 10th. The shares were sold at an average price of $4.75, for a transaction totalling $24,951.75. Learn More on Kinney Horn's trading history.
Who are Olema Pharmaceuticals' active insiders?: Olema Pharmaceuticals' insider roster includes Sean Bohen (CEO), Cyrus Harmon (CTO), and Kinney Horn (Insider). Learn More on Olema Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Olema Pharmaceuticals?: During the last twelve months, Olema Pharmaceuticals insiders bought shares 3 times. They purchased a total of 1,737,802 shares worth more than $17,849,606.18. During the last twelve months, insiders at the sold shares 18 times. They sold a total of 258,355 shares worth more than $3,164,592.47. The most recent insider tranaction occured on March, 28th when Director Cyrus Harmon sold 20,000 shares worth more than $219,400.00. Insiders at Olema Pharmaceuticals own 23.5% of the company. Learn More about insider trades at Olema Pharmaceuticals.
Information on this page was last updated on 3/28/2024.

Kinney Horn Insider Trading History at Olema Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/10/2022	Sell	5,253	$4.75	$24,951.75
1/10/2022	Sell	5,251	$6.85	$35,969.35
12/10/2021	Sell	5,251	$10.39	$54,557.89
10/11/2021	Sell	5,251	$27.90	$146,502.90
9/10/2021	Sell	5,251	$29.38	$154,274.38
8/10/2021	Sell	5,251	$25.71	$135,003.21	7,041
7/12/2021	Sell	5,251	$26.51	$139,204.01	7,041
6/10/2021	Sell	5,251	$29.72	$156,059.72	7,041
5/18/2021	Sell	57,763	$24.15	$1,394,976.45

Kinney Horn Buying and Selling Activity at Olema Pharmaceuticals

Olema Pharmaceuticals Company Overview

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Today's Range

Now: $10.15

$9.90

$10.20

50 Day Range

MA: $12.16

$9.87

$15.05

2 Week Range

Now: $10.15

$3.93

$17.79

Volume

546,692 shs

Average Volume

782,039 shs

Market Capitalization

$567.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Pentagon contract could send this $2 AI stock soaring

From Behind the Markets | Ad

Get all the info here >>>